dr. goy discusses ibrutinib with venetoclax in mcl
Published 6 years ago • 198 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
1:24
dr. goy on preliminary data with ibrutinib/venetoclax in relapsed/refractory mcl
-
1:25
dr. goy discusses single-agent ibrutinib in mcl
-
1:06
dr. goy on efficacy with ibrutinib in mcl
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
0:46
dr. goy compares acalabrutinib with ibrutinib in mcl
-
1:00
dr. goy on acalabrutinib versus ibrutinib in mcl
-
0:47
venetoclax plus ibrutinib combo shows potential in relapsed/refractory mcl
-
1:08
dr. tam on the toxicities of ibrutinib plus venetoclax in mcl
-
1:22
dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:25
dr. goy discusses challenges in treatment of mcl
-
1:08
dr. tam on the toxicity of ibrutinib plus venetoclax in mcl
-
1:28
dr. ritchie on immunological recovery with venetoclax and ibrutinib in mcl
-
1:56
dr. tam on the combination of ibrutinib plus venetoclax in mantle cell lymphoma
-
0:15
copy of dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
1:31
dr. goy on treating older patients with mcl
-
1:27
dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
-
2:00
dr. goy discusses btk inhibitors in mcl